Clinicopathologic and demographic evaluation of triple-negative breast cancer patients among a Turkish patient population: A single center experience

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 10, 2013, Pages 6013-6017

  Somali, Isil ^a   Ustaoglu, Bahar Yakut ^a   Tarhan, Mustafa Oktay ^a   Yigit, Seyran Ceri ^a   Demir, Lutfiye ^a   Ellidokuz, Hulya ^b   Erten, Cigdem ^a   Alacacioglu, Ahmet ^a  

^a IZMIR KATIP CELEBI UNIVERSITY   (Turkey)

^b DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

BMI; Breast cancer; Non triple negative breast cancer; Triple negative tumors

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BODY MASS; CANCER STAGING; CLINICAL TRIAL; DEMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; LUNG CARCINOMA; LYMPH NODE METASTASIS; METABOLISM; METASTASIS; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; PREMENOPAUSE; PROGNOSIS; RETROSPECTIVE STUDY; TRIPLE NEGATIVE BREAST CANCER; TURKEY (REPUBLIC); VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BODY MASS INDEX; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; DEMOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM STAGING; PREMENOPAUSE; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TRIPLE NEGATIVE BREAST NEOPLASMS; TURKEY; YOUNG ADULT;

EID: 84890443476     PISSN: 15137368     EISSN: None     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.10.6013     Document Type: Article

References (29)

1. Aksoy S, Dizdar O, Harputluoglu H, Altundag K (2007). Demographic, clinical, and pathological characteristics of Turkish triple-negative breast cancer patients: single center experience. Ann Oncol, 18, 1904-6.
2. Anders C, Carey LA (2008). Understanding and treating triplenegative breast cancer. Oncology (Williston Park), 22, 1233-9.
3. Bidard FC, Conforti R, Boulet T, et al (2007). Does triplenegative phenotype accurately identify basal-like tumour? An immunohistochemical analysis based on 143 'triple negative'breast cancers. Ann Oncol, 18, 1285-6.
4. Bulun SE, Chen D, Moy I, Brooks DC, Zhao H (2012). Aromatase, breast cancer and obesity: a complex interaction. Trends Endocrinol Metab, 23, 83-9.
5. Crabb SJ, Cheang MC, Leung S, et al (2008). Basal breast cancer molecular subtype predicts for lower incidence of axillary lymph node metastases in primary breast cancer. Clin Breast Cancer, 8, 249-56.
6. Daling JR, Malone KE, Doody DR, et al (2001). Relation of body mass index to tumor markers and survival among young women with invasive ductal breast carcinoma. Cancer, 92, 720-9.
7. De Onis M, Onyango AW, Borghi E, et al (2007). Development of a WHO growth reference for school-aged children and adolescents. Bull WHO, 85, 660-7.
8. Durnay A, Feugeas JP, Wittmer E, et al (2013). Distinct tumor protein p53 mutants in breast cancer subgroups. Int J Cancer, 132, 1227-31.
9. Federico A, Morgillo F, Tuccillo C, Ciardiello F, Loguercio C (2007). Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer, 121, 2381-6.
10. Fitzgibbons PL, Page DL, Weaver D, et al (2000). Prognostic factors in breast cancer. College of American pathologists consensus statement 1999. Arch Pathol Lab Med, 124, 966-78.
11. Foulkes WD, Smith IE, Reis-Filho (2010). Triple-negative breast cancer. N Engl J Med, 363, 1938-48.
12. Lahmann PH, Hoffmann K, Allen N, et al (2004). Body size and breast cancer risk: findings from the European prospective investigation into cancer and nutrition (EPIC). Int J Cancer, 111, 762-71.
13. Lara-Medina F, Pe'rez-Sa'nchez V, Saavedra-Pe'rez D, et al (2011). Triple-negative breast cancer in hispanic patients. Cancer, 117, 3658-69.
14. Lin NU, Vanderplas A, Hughes ME, et al (2012). Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the national comprehensive cancer network. Cancer, 118, 5463-72.
15. Millikan RC, Newman B, Tse CK, et al (2008). Epidemiology of basal-like breast cancer. Breast Cancer Res Treat, 109, 123-39.
16. Nielsen TO, Hsu FD, Jensen K, et al (2004). Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res, 10, 5367-74.
17. Oakman C, Viale G, Di Leo A (2010). Management of triple negative breast cancer. The Breast, 19, 312-21.
18. Oken MM, Creech RH, Tormey DC, et al (1982). Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol, 5, 649-55.
19. Perou CM, Sørlie T, Eisen MB, et al (2000). Molecular portraits of human breast tumours. Nature, 406, 747-52.
20. Phipps AI, Chlebowski RT, Prentice R, et al (2011). Body size, physical activity, and risk of triple-negative and estrogen receptor-positive breast cancer. Cancer Epidemiol Biomarkers Prev, 20, 454-63.
21. Pierobon M, Frankenfeld CL (2013). Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Res Treat, 137, 307-14.
22. Rakha EA, Reis-Filho JS, Ellis IO (2008). Basal-like breast cancer: a critical review. J Clin Oncol, 26, 2568-81.
23. Rose DP, Vona-Davis L (2010). Interaction between menopausal status and obesity in affecting breast cancer risk. Maturitas, 66, 33-8.
24. Sastre-Garau X, Jouve M, Asselain B, et al (1996). Infiltrating lobular carcinoma of the breast. Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer, 77, 113-20.
25. Sørlie T, Perou CM, Tibshirani R, et al (2001). Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA, 98, 10869-74.
26. Suzuki R, Orsini N, Saji S, Key TJ, Wolk A (2009). Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status: a meta-analysis. Int J Cancer, 124, 698-712.
27. Trivers KF, Lund MJ, Porter PL, et al (2009). The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control, 20, 1071-82.
28. Vona-Davis L, Rose DP (2007). Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocr Relat Cancer, 14, 189-206.
29. Yamamoto Y, Iwase H (2010). Clinicopathological features and treatment strategy for triple-negative breast cancer. Int J Clin Oncol, 15, 341-51.